Cost-effectiveness of 18F-fluorodeoxyglucose positron emission tomography in the assessment of early dementia from a Belgian and European perspective

European Journal of Neurology

Volumn 12, Issue 4, 2005, Pages 254-263

  Moulin Romsee, G ^a   Maes, A ^a   Silverman, D ^b   Mortelmans, L ^a   Van Laere, Koen ^a,c  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Alzheimer's disease; Cost evaluation; Diagnosis; FDG PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ALZHEIMER DISEASE; BELGIUM; COGNITIVE DEFECT; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DEMENTIA; DIAGNOSTIC ACCURACY; ECONOMIC ASPECT; EUROPE; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; ALGORITHM; ARTICLE; CASE CONTROL STUDY; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; METABOLISM; PREDICTION AND FORECASTING; REPRODUCIBILITY; SCINTISCANNING;

ALGORITHMS; CASE-CONTROL STUDIES; COST-BENEFIT ANALYSIS; DEMENTIA; EUROPE; FLUORODEOXYGLUCOSE F18; HUMANS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 16444384151     PISSN: 13515101     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2004.00940.x     Document Type: Review

References (41)

1. Alexander GE, Chen K, Pietrini P et al (2002). Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry 159:738-745.
2. Arnaiz E., Jelic V, Almkvist O et al. (2001). Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport 12:851-855.
3. Bachman DL, Wolf PA, Linn RT et al, (1993). Incidence of dementia and probable Alzheimer's disease in a general population: the Framingham Study. Neurology 43:515-519.
4. Burns A, Rossor M, Hecker J et al. (1999). The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord 10:237-244.
5. Chetelat G, Desgranges B, de la Sayette V et al. (2003) Mild cognitive impairment: can FDG PET predict who is to rapidly convert to Alzheimer's disease? Neurology 60:1374-1377.
6. Chui H, Zhang Q (1997). Evaluation of dementia: a systematic study of the usefulness of the American Academy of Neurology's practice parameters. Neurology 49:925-935.
7. Corey-Bloom J. Thal L, Galasko D et al. (1995). Diagnosis and evaluation of dementia. Neurology 45:211-218.
8. Corey-Bloom J, Anand R, Veach J (1998). A randomized trial evaluating the efficacy and safety of ENA 713 rivastigmine tartrate, a new acetyl cholinesterase inhibitor in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol 1:55-65.
9. Coyle J, Kershaw P (2001). Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease. Biol Psychiatry 49:289-299.
10. van Crevel H, van Gool WA, Walstra GJ (1999). Early diagnosis of dementia: which tests are indicated? What are their costs? J Neurol 246:73-78.
11. Doody RS, Geldmacher DS, Gordon B et al. (2001). Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 58:427-433.
12. Drummond MF, O'Brien B, Stoddart GL, Torrance GW (1997). Methods for the,Economic Evaluation of Health Care Programmes, 2nd edn. Oxford University Press, Oxford.
13. Freter S, Bergman H, Gold S et al. (1998). Prevalence of potentially reversible dementias and actual reversibility in a memory clinic cohort. C M A J 159:657-662.
14. Galasko D, Hansen LA, Katzman R et al. (1994). Clinical-neuropathological correlations in Alzheimer's disease and related dementias. Arch Neurol 51:888-895.
15. Gambhir SS, Schwimmer J (2000). Economic evaluation studies in nuclear medicine: a methodological review of the literature. Q J Nucl Med 44:121-137.
16. Herholz K. Salmon E, Perani D et al. (2002). Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. NeuroImage 17:302-316.
17. Herholz K, Schopphoff H, Schmidt M et al. (2003). Direct comparison of spatially normalized PET and SPECT scans in Alzheimer's disease. j Nucl Med 43:21-26.
18. Hoffman JM, Hanson MW, Welsh KA et al. (1996). Interpretation variability of 18FDG-positron emission tomography studies in dementia. Invest Radiol 31:316-322.
19. Hoffman JM, Welsh-Bohmer KA, Hanson M et al. (2000). FDG PET imaging in patients with pathologically verified dementia. J Nucl Med 41:1920-1928.
20. Holmes C, Cairns N, Lantos P, Mann A (1999). Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies. Br J Psychiatry 174:45-50.
21. Imbimbo BP, Verdelli G, Martelli P, Marchesini D (1999). Two-year treatment of Alzheimer's disease with eptastigmine. The Eptastigmine Study Group. Dement Geriatr Cogn Disord 10:139-147.
22. Ishii K, Willoch F, Minoshima S et al. (2001). Statistical brain mapping of 18F-FDG PET in Alzheimer's disease: validation of anatomic standardization for atrophied brains. J Nucl Med 42:548-557.
23. Jobst KA, Barnetson LP, Shepstone BJ. (1998). Accurate prediction of histologically confirmed Alzheimer's disease and the differential diagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-ray CT, and Apo E4 in medial temporal lobe dementias. Oxford Project to Investigate Memory and Aging. Int Psychogeriatr 10:271-302.
24. Knopman DS, DeKosky ST, Cummings JL et al. (2001). Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American, Academy of Neurology. Neurology 56:1143-1153.
25. Lim A, Tsuang D, Kukull W et al. (1999). Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series. J Am Geriatr Soc 47:564-569.
26. Mohs RC, Doody RS, Morris JC et al. (2001). A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 57:481-488.
27. Morris JC, Storandt M, McKeel DW et al. (1996). Cerebral amyloid deposition and diffuse plaques in 'normal' aging: evidence for presymptomatic and very mild Alzheimer's disease. Neurology 46:707-719.
28. Pacolet J (2001). Costs for Care of Alzheimer Patients in Flanders and Europe: Results of a Pilot Study in Flanders, Finland, Greece, Ireland and Spain. KULeuven Press, Leuven.
29. Petersen RC, Stevens JC, Ganuli M et al. (2001). Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56:1133-1142.
30. Potkin SG, Alva G, Keator D et al. (2002). Brain metabolic effects of Neotrofin in patients with Alzheimer's disease. Brain Res 951:87-95.
31. Raskind MA, Peskind ER, Wesel T, Yuan W (2000). Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 54:2261-2268.
32. Rogers SL, Friedhoff LT (1996). The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group. Dementia 7:293-303.
33. Rogers SL, Friedhoff LT (1998). Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 8:67-75.
34. Rosier M. Anand R, Cican-Sain A et al. (1999). Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. B M J 318:633-638.
35. Sano M, Ernesto C, Thomas RG et al. (1997). A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 336:1216-1222.
36. Silverman DH, Small GW, Phelps ME (1999). Clinical value of neuroimaging in the diagnosis of dementia: sensitivity and specificity of regional cerebral metabolic and other parameters for early identification of Alzheimer's disease. Clin Positron Imaging 2:119-130.
37. Silverman DH, Small GW, Chang CY et al. (2001). Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 286:2120-2127.
38. Silverman DH, Gambhir SS, Huang HW et al. (2002a). Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits. J Nucl Med 43:253-266.
39. Silverman DH, Cummings JL, Small GW et al. (2002b). Added clinical benefit of incorporating FDG PET into clinical evaluation of patients with cognitive impairment. Mol Imaging Biol 4:283-293.
40. Small GW, Ercoli LM, Silverman DH et al. (2000). Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 97:6037-6042.
41. Victoroff J, Mack W, Lyness SA, Chui HC (1995). Multicenter clinicopathological correlation in dementia. Am J Psychiatry 152:1476-1484.